NASDAQ:GNFT • US3722791098
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GENFIT-ADR (GNFT).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-09-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-06-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-06-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-04-17 | HC Wainwright & Co. | Maintains | Buy |
| 2022-04-11 | SVB Leerink | Maintains | Outperform |
| 2021-12-20 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2021-09-30 | HC Wainwright & Co. | Maintains | Neutral |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 26.566M -68.96% | 38.176M 43.70% | 70.939M 85.82% | 52.142M -26.50% | 48.45M -7.08% | 58.242M 20.21% | 59.873M 2.80% | 72.375M 20.88% | 145.1M 100.48% | 178.55M 23.05% | 233.04M 30.52% | |
| EBITDA YoY % growth | -25.473M -172.80% | -25.007M 1.83% | 4.949M 119.79% | -30.94M -725.18% | -19.72M 36.26% | -6.8M 65.52% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -27.305M -184.67% | -26.661M 2.36% | 3.225M 112.10% | -17.707M -649.06% | -27.479M -55.18% | -13.583M 50.57% | -25.64M -88.76% | -33.432M -30.39% | 36.708M 209.80% | 64.212M 74.93% | 103.83M 61.70% | |
| Operating Margin | -102.78% | -69.84% | 4.55% | -33.96% | -56.72% | -23.32% | -42.82% | -46.19% | 25.30% | 35.96% | 44.55% | |
| EPS YoY % growth | N/A 41.79% | N/A 79.37% | N/A 325.98% | -0.34 -192.65% | -0.67 -100.00% | -0.39 42.52% | -0.29 24.23% | N/A | N/A | N/A | N/A |
All data in EUR
| Q4 / 25 | |
|---|---|
| EPS Q2Q % growth | 0.02 103.06% |
| Revenue Q2Q % growth | 42.942M 434.84% |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | 3.621M 112.96% |
All data in EUR
13 analysts have analysed GNFT and the average price target is 9.84 USD. This implies a price increase of 102.95% is expected in the next year compared to the current price of 4.85.
GENFIT-ADR (GNFT) will report earnings on 2026-04-22, after the market close.
The consensus EPS estimate for the next earnings of GENFIT-ADR (GNFT) is 0.02 USD and the consensus revenue estimate is 42.94M USD.
The number of analysts covering GENFIT-ADR (GNFT) is 13.